clinical trial · NCT07147049
Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.·phase2·recruiting·n = 72
Moderate to Severe Acute Postoperative PainHL-1186HL-1186 placebo
brief summary
This is a multiple-center, randomized, double-blind, placebo-controlled study design evaluating the safety, efficacy, and pharmacokinetics (PK) parameter of HL-1186 tablet for moderate to severe acute pain after surgery.
started
Aug 8, 2025
primary completion
Dec 1, 2025
completion
Jan 1, 2026
last updated
Dec 22, 2025
official title
A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol